Get the Daily Brief
Latest Biotech News
Regulatory advance: FDA accepts Telix resubmitted NDA for TLX101-Px glioma imaging
The U.S. FDA accepted Telix Pharmaceuticals’ resubmitted NDA for TLX101-Px (Pixclara), a radiolabeled imaging agent intended to characterize progressive or recurrent glioma in both adults and...
CAR-T manufacturing and clinical iteration: modulating CAR T receptor affinity for efficacy vs safety
Researchers reported a strategy to optimize CAR T-cell therapy by precisely modulating receptor affinity, aiming to balance antitumor efficacy with safety. The work frames receptor affinity as a...
Novel accelerant for ITP: mezagitamab lifts platelet counts in Phase 2
Replimune-free? No—separate development: a Phase 2 trial report indicates mezagitamab, an investigational antibody for immune thrombocytopenia (ITP), significantly increased platelet counts in...
AI and automation to scale targeted biologic development (ADCs and assay reproducibility)
Agilent highlighted how lab automation can scale characterization workflows for antibody-drug conjugates (ADCs) and other targeted biologics, focusing on faster, more reproducible development....
CRO capability expansion: FairJourney Bio opens cryo-EM structural biology facility in San Diego
FairJourney Bio opened a new cryo-electron microscopy (cryo-EM) structural biology facility in San Diego, expanding its U.S. footprint and integrating atomic-resolution structure capabilities into...
Oral obesity competition heats up: Lilly launches Foundayo and steps into Wegovy pill battle
Eli Lilly launched its oral obesity pill Foundayo, entering direct competition with Novo Nordisk’s oral Wegovy and intensifying the pricing-and-access push in the rapidly expanding GLP-1 category....
Financing: Chapter raises $100M to target Medicare mismatches for seniors
Chapter raised $100 million in a Series E round to address “Medicare mismatches” affecting seniors, according to a report describing the company’s funding and investor participation. The financing...
Platform funding: Realta secures another $40M for hypoxic ischemic encephalopathy treatment
Realta Life Sciences raised an additional $40 million in the final tranche of its Series A round, bringing total funding to more than $150 million. The company’s program targets hypoxic ischemic...
FDA rejection hits Replimune’s melanoma program again
The FDA rejected Replimune’s oncolytic virus therapy RP-1 for advanced melanoma for a second time, according to multiple reports citing the agency’s rationale around unresolved trial doubts. The...
Oricell raises pre-IPO funding to push GPC3 solid-tumor CAR-T
Oricell Therapeutics secured more than $110 million in a pre-IPO round to expand its global footprint and move its lead GPC3-targeted autologous CAR-T therapy toward registrational trials. The...
FDA accepted Telix’s resubmitted brain imaging NDA
The FDA accepted for review Telix Pharmaceuticals’ resubmitted NDA for TLX101-Px (Pixclara, 18F-floretyrosine), a radiolabeled imaging agent intended to characterize progressive or recurrent...
Gilead and Kymera extend protein-degrader bets with KT-200 license
Gilead exercised its option to exclusively license Kymera Therapeutics’ KT-200, an oral CDK2 molecular glue degrader candidate, according to the companies. The move expands Gilead’s oncology...
Roche and C4 Therapeutics sign deal for degrader-antibody conjugates
Roche struck a new collaboration with C4 Therapeutics focused on degrader-antibody conjugates (DACs), pairing C4’s targeted protein degradation platform with Roche’s antibody and ADC delivery...
Biopharma financing and IPO market rebound signals renewed risk appetite
New financing snapshots and broader market coverage point to a strengthening early-2026 fundraising environment for biopharma. Separate reports show Q1 2026 biopharma financings reaching $22.82...
Luminai raises $38M with Cleveland Clinic to automate hospital operations
Luminai raised $38 million in Series B funding to scale its AI platform for automating healthcare administrative workflows, with Cleveland Clinic identified as a key partner for expansion. The...
Oricell and CAR-T expansion continues alongside regulatory uncertainty in melanoma
Carcinoma and oncology finance news continued to dominate the life-science capital flow picture, with Oricell expanding its solid-tumor CAR-T efforts through pre-IPO funding. At the same time,...
Material-to-drug pipeline: new CRISPR/CAR-T adjacent manufacturing and diagnostics signals
Beyond therapeutics, the dataset shows manufacturing and diagnostic infrastructure moves that can affect drug-development throughput. Telix’s FDA acceptance for TLX101-Px is one example of...
FDA and biotech policy signals: PDUFA approach shifts and review mechanics
Policy coverage in the dataset points to a shifting regulatory economics framework for first-in-human (FIH) trials under PDUFA reauthorization. One report says the FDA is moving from punitive fee...
FDA actions: Replimune’s melanoma therapy faces another rejection
The FDA has rejected Replimune Group’s engineered oncolytic virus therapy, RP-1, for advanced melanoma for a second time, escalating scrutiny of the dataset behind the application. The decision...
Capital markets: Oricell raises for solid-tumor CAR-T buildout
Oricell Therapeutics closed a pre-IPO funding round of more than $110 million to accelerate its GPC3-targeted autologous CAR-T for liver cancer, with a pathway toward registrational trials. The...